Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Midcaps, smallcaps buck trend
Wed, 24 Aug 11:30 am

Indian stock market indices continued to trade weak during the previous two hours of trade on the back of persistent selling across heavyweights. While stocks from the consumer durables and healthcare space are finding favour, IT stocks are at the receiving end.

The BSE-Sensex is down by 74 points and NSE-Nifty is down by 18 points at the moment. BSE-Midcap and BSE-Small cap indices are up by 0.56% and 0.77% respectively. The rupee is trading at 45.74 to the US dollar.

Retailing stocks are trading mixed. While Koutons Retail and Zodiac Clothing are in the green, Trent and Pantaloon are trading weak. As per a leading financial daily, Titan Industries, the watches to jewellery maker, is exploring options of getting into newer product lines. It aims to become a full fledged lifestyle retailing chain. As per the management, the objective is to enter new verticals every second year and try and gain leadership there. The retailing company has in the past gotten into fashion accessories like belts and sunglasses. It wants to position itself as a one stop shop for all lifestyle customer requirements ranging from watches to leather accessories to footwear. This year, the company is planning to launch silver watches and helmets. It may be noted that the company has been opening more and more stores across India for its watches, jewellery as well as fashion merchandise.

Pharma stocks are trading in the green. Lupin and Ranbaxy are the biggest gainers, while Glenmark and Sun Pharma are the biggest losers. According to a leading financial daily, Aventis Pharma, the 50% subsidiary of Sanofi-Aventis SA, France is close to buying the over the counter (OTC) business of Universal Medicare Limited for Rs 5 bn. Sanofi's OTC business in India is quite low and this deal will give boost to the French company's OTC business in India. The products included in the deal have annual sales of Rs 10 to 15 bn and the OTC segment is expected to grow at 17% to 18%, much higher than the expected growth of the overall pharmaceutical sector. The deal covers 30 brands sold by India based Universal Medicare and is expected to be signed in a couple of days.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Midcaps, smallcaps buck trend". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.